2 news items
FDA Grants Full Approval for TIVDAK® to Treat Recurrent or Metastatic Cervical Cancer
GMAB
PFE
29 Apr 24
reactions occurred in 1.6% of patients who received TIVDAK, including acute kidney injury, pneumonia, sepsis, and SJS (each 0.4
TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer
GMAB
PFE
29 Apr 24
%). Fatal adverse reactions occurred in 1.6% of patients who received TIVDAK, including acute kidney injury, pneumonia, sepsis, and SJS
- Prev
- 1
- Next